<DOC>
	<DOCNO>NCT00219791</DOCNO>
	<brief_summary>To evaluate safety efficacy glucarpidase patient impaired methotrexate ( MTX ) clearance owe MTX-induced renal failure follow high-dose MTX therapy , intrathecal MTX overdose .</brief_summary>
	<brief_title>Study Glucarpidase ( CPG2 ) Management Patients With Delayed Methotrexate Clearance</brief_title>
	<detailed_description />
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Written inform consent patient legally valid representative Patients receive highdose MTX ( &gt; 1 g/m2 body surface area ( BSA ) give infusion 24 hour ) treatment ALL , NHL solid tumour ( e.g . osteosarcoma ) Age ≥ 18 year Serum MTX &gt; 5 µmol/L 42 hour later start MTX infusion , serum MTX &gt; 1 μmol/L 42 hour later start MTX infusion together renal insufficiency , serum MTX &gt; 0.4 µmol/L 48 hour later start MTX infusion together renal insufficiency . Renal insufficiency define serum creatinine &gt; 1.5 × upper limit normal ( ULN ) and/or oliguria ( urine output &lt; 500 mL/24 hour despite adequate hydration , diuretic alkalinisation ) . Pregnant lactating female Unwillingness patient relative/legal representative give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>methotrexate</keyword>
	<keyword>delay elimination</keyword>
	<keyword>renal insufficiency</keyword>
	<keyword>CPG2</keyword>
	<keyword>Voraxaze</keyword>
</DOC>